Publicacións en colaboración con investigadores/as de Hospital Universitario de Salamanca (12)

2024

  1. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-related cancer

  2. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

  3. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

    Pituitary, Vol. 27, Núm. 5, pp. 497-506

  4. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

2022

  1. Aetiological diagnosis of hyponatraemia in non-critical patients on total parenteral nutrition: A prospective multicentre study

    Endocrinologia, Diabetes y Nutricion, Vol. 69, Núm. 3, pp. 160-167

  2. Process of medical nutrition therapy

    Nutricion Hospitalaria, Vol. 39, Núm. 5, pp. 1166-1189

2020

  1. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834

2019

  1. Development of hyponatremia in non-critical patients receiving total parenteral nutrition: A prospective, multicenter study

    Clinical Nutrition, Vol. 38, Núm. 6, pp. 2639-2644

2017

  1. MKK6 controls T3-mediated browning of white adipose tissue

    Nature Communications, Vol. 8, Núm. 1

2016

  1. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry

    Journal of Clinical Lipidology, Vol. 10, Núm. 4, pp. 953-961

2003

  1. Adenoma ovárico de células de Leydig: Una rara causa de virilización asociada a factores de riesgo cardiovascular

    Endocrinologia y Nutricion, Vol. 50, Núm. 4, pp. 145-148

2000

  1. A comparative evaluation of amlodipine and hydrochlorothiazide as monotherapy in the treatment of isolated systolic hypertension in the elderly

    Clinical Drug Investigation, Vol. 19, Núm. 5, pp. 317-326